Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer

Radiopharm Theranostics announced that the US FDA has granted Orphan Drug Designation to Ga68-Trivehexin, RAD 301, radiopharmaceutical technology for imaging of patients with PDAC.